HRMY on Nasdaq

Harmony Biosciences Holdings, Inc.

American pharmaceutical preparations company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with ANI PHARMACEUTICALS INC, Arrowhead Pharmaceuticals or TELIX PHARMACEUTICALS LIMITED, or pick any stock.

  • TickerHRMY on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersDE
  • Incorporated inDE2
  • Business address630 W Germantown Pike, Suite 215, Plymouth Meeting, Pa 194622
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

77.2%Gross margin3
24.0%Operating margin3
18.3%Net margin3
21.5%Revenue growth, 20253
18.2%Return on equity3
0.17×Debt to equity3
$347.9MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue23¢$198.3M
  • Research and development22¢$189.6M
  • Other costs31¢$265.5M
  • Income tax6¢$56.4M
  • Profit18¢$158.7M

Out of $868.5M in revenue.3

Where each dollar of operating cash went, fiscal 2025

  • Capital spending0¢$310.0K
  • Kept or used elsewhere100¢$347.9M

Out of $348.2M of cash from operations.3

Financial statements

Revenue45673$868.5M in 2025+14386% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $6.0M$6.0M20192020: $159.7M$159.7M2020+2565%2021: $305.4M$305.4M2021+91%2022: $437.9M$437.9M2022+43%2023: $582.0M$582.0M2023+33%2024: $714.7M$714.7M2024+23%2025: $868.5M$868.5M2025+22%
Gross profit45673$670.1M in 2025+15068% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $4.4M$4.4M20192020: $132.0M$132.0M2020+2888%2021: $249.9M$249.9M2021+89%2022: $354.4M$354.4M2022+42%2023: $460.8M$460.8M2023+30%2024: $557.9M$557.9M2024+21%2025: $670.1M$670.1M2025+20%
Operating income45673$208.5M in 2025
-$200.0M-$100.0M0$100.0M$200.0M$300.0M2019: -$145.9M-$145.9M20192020: $17.0M$17.0M20202021: $87.5M$87.5M2021+415%2022: $120.2M$120.2M2022+37%2023: $192.0M$192.0M2023+60%2024: $190.8M$190.8M2024−1%2025: $208.5M$208.5M2025+9%
Net income45673$158.7M in 2025
-$200.0M-$100.0M0$100.0M$200.0M2019: -$152.0M-$152.0M20192020: -$36.9M-$36.9M2020−76%2021: $34.6M$34.6M20212022: $181.5M$181.5M2022+425%2023: $128.9M$128.9M2023−29%2024: $145.5M$145.5M2024+13%2025: $158.7M$158.7M2025+9%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Net product revenue$868.5M$714.7M$582.0M
Cost of product sold$198.3M$156.8M$121.2M
Gross profit$670.1M$557.9M$460.8M
Sales and marketing$119.5M$110.9M$97.4M
General and administrative$152.5M$110.4M$95.3M
Total operating expenses$461.6M$367.1M$268.8M
Operating income$208.5M$190.8M$192.0M
Loss on debt extinguishment-$9.8M
Other (expense) income, net-$680.0K-$68.0K$159.0K
Interest expense-$14.6M-$17.5M-$23.8M
Interest income$21.9M$18.5M$14.7M
Income before income taxes$215.1M$191.8M$173.4M
Income tax expense-$56.4M-$46.3M-$44.5M
Net income$158.7M$145.5M$128.9M
Unrealized income on investments$280.0K$64.0K$153.0K
Comprehensive income$159.0M$145.6M$129.0M
Basic$2.76$2.56$2.17
Diluted$2.71$2.51$2.13
Weighted average number of shares of common stock - basic57.5M shares56.9M shares59.5M shares
Weighted average number of shares of common stock - diluted58.5M shares57.9M shares60.4M shares
Research and development$189.6M$145.8M$76.1M

Compare Harmony Biosciences Holdings, Inc. with another company

Leadership

Who has led Harmony Biosciences Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John C. Jacobs2020–2022
  2. Jeffrey M. Dayno2023–now

President

  1. John C. Jacobs2020–2022
  2. Jeffrey M. Dayno2023–now

Chief financial officer

  1. Susan L. Drexler2020
  2. Sandip Kapadia2021–2026
  3. Glenn Reicin2026–now

Chief operating officer

  1. Peter Anastasiou2026–now
2025
Board members and other officers (21)

Timeline

  1. May 30, 2023New chief executive Jeffrey M. Dayno becomes CEO11
  2. Aug 18, 2020New chief executive John C. Jacobs becomes CEO12

Filings

349 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 63 major events, 157 insider forms, 28 large holders, 80 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Sep 18, 20264 EDGAR
  3. Sep 18, 2026144 EDGAR
  4. Sep 17, 2026144 EDGAR
  5. Sep 16, 2026144 EDGAR
  6. Sep 9, 20264 EDGAR
  7. Sep 8, 2026144 EDGAR
  8. Sep 4, 2026144 EDGAR
  9. Aug 7, 2026144 EDGAR
  10. Aug 4, 202610-Q EDGAR
  11. Aug 4, 20268-K EDGAR
  12. Jul 31, 2026SCHEDULE 13G EDGAR
  13. Jul 28, 2026SCHEDULE 13G/A EDGAR
  14. Jul 22, 20263 EDGAR
  15. Jul 16, 20268-K EDGAR
  16. Jul 2, 2026144 EDGAR
  17. Jun 30, 2026144 EDGAR
  18. Jun 26, 2026144 EDGAR
  19. Jun 24, 2026144 EDGAR
  20. Jun 9, 2026144 EDGAR

The 349 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 28 such filings since October 2021, the latest 10:

  1. Jul 31, 2026SCHEDULE 13G
  2. Jul 28, 2026SCHEDULE 13G/A
  3. Mar 27, 2026SCHEDULE 13G/A
  4. Feb 5, 2026SCHEDULE 13G/A
  5. Nov 14, 2025SCHEDULE 13G/A
  6. Nov 5, 2025SCHEDULE 13G/A
  7. Feb 12, 2025SCHEDULE 13G/A
  8. Feb 10, 2025SCHEDULE 13G/A
  9. Feb 5, 2025SCHEDULE 13G/A
  10. Jan 30, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.7,101,965$258.6M0.0%+31,930
Fmr LLC3,574,115$130.1M0.0%+416,476
Vanguard Portfolio Management LLC2,880,489$104.9M0.0%+166,136
American Century Companies Inc2,539,512$92.5M0.0%+434,333
Dimensional Fund Advisors LP2,393,588$87.1M0.0%+317,078
Vanguard Capital Management LLC2,105,053$76.6M0.0%+2,738
State Street Corp1,859,322$67.7M0.0%+74,960
Armistice Capital, LLC1,564,000$56.9M1.6%−60,000
Geode Capital Management, LLC1,442,649$52.5M0.0%+119,929
Arrowstreet Capital, Limited Partnership1,312,550$47.8M0.0%−69,563
Renaissance Technologies LLC1,195,371$43.5M0.1%+118,000
Two Sigma Investments, LP959,136$34.9M0.0%+225,693
Aqr Capital Management LLC934,326$34.0M0.0%+218,080
Valor Management LLC818,013$29.8M0.0%+700,883
Morgan Stanley733,684$26.7M0.0%−297,334
UBS Group AG602,990$22.0M0.0%+154,999
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main551,075$20.1M0.0%−16,040
Invesco Ltd.528,520$19.2M0.0%−99,727
Jpmorgan Chase & Co514,085$18.2M0.0%−309,428
venBio Partners LLC472,194$17.2M3.3%−17,000
Northern Trust Corp471,221$17.2M0.0%+47,992
Bnp Paribas Financial Markets438,302$16.0M0.0%−106,886
Charles Schwab Investment Management Inc423,824$15.4M0.0%+12,227
Nomura Holdings Inc417,932$15.2M0.1%−103,015
Goldman Sachs Group Inc403,532$14.7M0.0%−835,675

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34